1,122 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Teva: A Better Entry Point Post-Results https://seekingalpha.com/article/4170428-teva-better-entry-point-post-results?source=feed_tag_israel May 06, 2018 - Teva reported market-beating Q1 2018 results before the market opened on Thursday, but its share price eventually ended the day down 4.4 percent.An upward revision to the 2018 guidance also failed to
Bright Lights On Capitalist Woodstock, Tech Developers And Sports Betting https://seekingalpha.com/article/4170254-bright-lights-capitalist-woodstock-tech-developers-sports-betting?source=feed May 05, 2018 - Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Kiniksa Pharmaceuticals Files For $100 Million IPO https://seekingalpha.com/article/4169845-kiniksa-pharmaceuticals-files-100-million-ipo?source=feed_tag_ipo_analysis May 04, 2018 - Kiniksa Pharma has filed an initial registration statement for a U.S. IPO.The firm is a mid-stage developer of treatments for autoimmune and inflammatory diseases.KNSA shows promise but the IPO is unu
Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication http://www.zacks.com/stock/news/302470/pharma-stock-roundup-mixed-q1-for-mrk-pfe-fda-nod-for-kymriahs-2nd-indication?cid=CS-ZC-FT-302470 May 04, 2018 - Earnings are in focus this week with Pfizer (PFE) and Merck (MRK) delivering mixed Q1 numbers. Novartis gains FDA approval for the second indication of its CAR-T therapy, Kymriah.
Actinium Pharmaceuticals: Neglected Assets In Niche Oncology https://seekingalpha.com/article/4166543-actinium-pharmaceuticals-neglected-assets-niche-oncology?source=feed_tag_editors_picks May 04, 2018 - Significant hires, partnership activity, and an important data readout later this year point towards an inflection point in ATNM.We believe that the company's drug candidates benefit from significant
Allergan: Too Much Focus On The Bad https://seekingalpha.com/article/4168557-allergan-much-focus-bad?source=feed_sector_healthcare May 02, 2018 - Allergan spends entirely too much time discussing strategic alternatives for a growing business.The company continues to shake off LOE issues with expectations to grow EPS.The Botox market is expected
Miracle Mile Advisors, LLC Buys First Trust Preferred Securities and Income ETF, Vanguard FTSE ... http://www.gurufocus.com/news/675169/miracle-mile-advisors-llc-buys-first-trust-preferred-securities-and-income-etf-vanguard-ftse-developed-markets-ishares-california-muni-bond-sells-wisdomtree-europe-hedged-equity-fund-ishares-sp-500-value-ishares-13-year-credit-bond-etf May 02, 2018 - Miracle Mile Advisors, LLC Buys First Trust Preferred Securities and Income ETF, Vanguard FTSE Developed Markets, iShares California Muni Bond, Sells WisdomTree Europe Hedged Equity Fund, iShares S&P 500 Value, iShares 1-3 Year Credit Bond ETF, Stocks: VEA,IEMG,AAPL,AGN,GOOGL,FB,FPE,CMF,SCZ,IXC,BAC,AMZ, release date:May 02, 2018
Your Daily Pharma Scoop: KPTI Data, Allergan Write-Off, Celgene Down On Delay https://seekingalpha.com/article/4167994-daily-pharma-scoop-kpti-data-allergan-write-celgene-delay?source=feed_sector_healthcare May 02, 2018 - KPTI is up on strong data from MM study.Allergan writes off its entire Vitae acquisition.Celgene is down on ozanimod resubmission delay.
Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring http://www.zacks.com/stock/news/301968/ironwood-irwd-incurs-loss-in-q1-announces-restructuring?cid=CS-ZC-FT-301968 May 02, 2018 - Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.
Allergan Abandons Psoriasis Program, But Remains Steady With Acute Migraine Treatment https://seekingalpha.com/article/4168332-allergan-abandons-psoriasis-program-remains-steady-acute-migraine-treatment?source=feed_sector_healthcare May 02, 2018 - Allergan announces write off for drug purchased from Vitae to treat psoriasis.The recent trial success for the acute migraine study should overshadow this bad news about abandonment of the psoriasis p

Pages: 1234567891011...113

<<<Page 6>